Health Care • Medical/Dental Instruments
$5.52 ▼ -0.03
(-0.54%)
MKT CAP: $8.9M • VOL: 12.8K
52W L $1 52W H $26
ROARABLE / RQD
D • 44/100
PIOTROSKI
3 / 9
AEMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.3M | -$9.3M | -$12.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.2M | -$13.4M | -$12.2M |
| EBITDA (Normalized) | -$7.3M | -$9.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.0M | -$7.6M | -$10.1M |
| Capital Expenditures (CapEx) | $3.7K | $0 | — |
| Free Cash Flow (FCF) | -$7.0M | -$7.6M | -$10.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.0M | $4.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.7M | $4.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AEMD.